Literature DB >> 8102022

Effect of S-emopamil, nimodipine, and mild hypothermia on hippocampal glutamate concentrations after repeated cerebral ischemia in rabbits.

M Matsumoto1, M S Scheller, M H Zornow, M A Strnat.   

Abstract

BACKGROUND AND
PURPOSE: We sought to determine the effects of two different calcium channel antagonists, S-emopamil and nimodipine, on hippocampal glutamate and glycine release and to compare their effects to those of mild hypothermia.
METHODS: New Zealand White rabbits were subjected to two 7.5-minute episodes of global cerebral ischemia at a 1-hour interval produced by neck tourniquet inflation (20 psi) combined with hypotension during halothane anesthesia. Hippocampal extracellular concentrations of glutamate and glycine were monitored using in vivo microdialysis. Animals were randomized to receive either S-emopamil (1 mg.kg-1 bolus, 0.1 mg.kg-1.min-1 infusion), nimodipine (10 micrograms.kg-1 bolus, 1 microgram.kg-1.min-1 infusion), hypothermia (32 degrees C), or saline (control) before ischemia. Drug infusion and hypothermia were continued throughout the study periods.
RESULTS: In all four groups, both ischemic episodes resulted in significant elevations of hippocampal extracellular concentrations of glutamate and glycine (baseline vs peak, P < .01 in all groups). However, glutamate levels were significantly lower in the S-emopamil (P = .0001) and hypothermia (P = .0003) groups when compared with the control group after the onset of the first ischemic episode through 1 hour after the second ischemic episode. There was no significant difference between the four groups in the concentrations of glycine. There was no significant difference between the peak concentrations of glutamate or glycine after each ischemic period.
CONCLUSIONS: These results suggest that preischemic administration of S-emopamil, but not nimodipine, attenuates the increase in hippocampal extracellular concentrations of glutamate in the peri-ischemic period in this model, and that this effect is also observed when mild hypothermia is instituted before ischemia. Decreased concentrations of glutamate after ischemic episodes may be a possible mechanism for the observed neuroprotective properties of S-emopamil and mild hypothermia (32 degrees C).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102022     DOI: 10.1161/01.str.24.8.1228

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

1.  Neuroprotective effects by nimodipine treatment in the experimental global ischemic rat model : real time estimation of glutamate.

Authors:  Seok Keun Choi; Gi-Ja Lee; Samjin Choi; Youn Jung Kim; Hun-Kuk Park; Bong Jin Park
Journal:  J Korean Neurosurg Soc       Date:  2011-01-31

Review 2.  Mechanisms of ischemic brain damage.

Authors:  Kristian P Doyle; Roger P Simon; Mary P Stenzel-Poore
Journal:  Neuropharmacology       Date:  2008-01-25       Impact factor: 5.250

Review 3.  Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease.

Authors:  Kota Kurisu; Jong Youl Kim; Jesung You; Midori A Yenari
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

4.  Effects of mild hypothermia on the release of regional glutamate and glycine during extended transient focal cerebral ischemia in rats.

Authors:  F P Huang; L F Zhou; G Y Yang
Journal:  Neurochem Res       Date:  1998-07       Impact factor: 3.996

5.  Differential inhibition of neuronal calcium entry and [3H]-D-aspartate release by the quaternary derivatives of verapamil and emopamil.

Authors:  R A Keith; T J Mangano; P A DeFeo; G E Ernst; E J Warawa
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

6.  In vitro and in vivo evaluation of hypothermia on pharmacokinetics and pharmacodynamics of nimodipine in rabbits.

Authors:  Yu-Xing Fei; Tian-Hong Zhang; Jing Zhao; He Ren; Ya-Nan Du; Chun-Ling Yu; Qiang Wang; Shu Li; Ting-Lin Ren; Qiang Jian; Shu-Yang Fei; Zhen-Qing Zhang; Yi Zhang
Journal:  J Int Med Res       Date:  2017-08-29       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.